Vericel (VCEL) Raw Materials (2014 - 2026)
Vericel (VCEL) posted Raw Materials of $14.0 million for Q2 2026, up 1.82% sequentially from $13.8 million in Q1 2026, and up 24.61% YoY from $11.2 million in Q2 2025.
Vericel (VCEL) Raw Materials (2014 - 2026) Analysis & Trends
Vericel has reported Raw Materials for 13 years, with the latest figure at $14.0 million in Q2 2026.
- Quarterly Raw Materials rose 24.61% year-over-year to $14.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $14.0 million (up 24.61% YoY) and the FY2025 annual result came in at $13.0 million, up 0.98% from the prior year.
- Raw Materials improved to $14.0 million in Q2 2026 per VCEL's latest filing, from $13.8 million in the prior quarter.
- Over five years, Raw Materials peaked at $15.8 million in Q3 2022 and troughed at $10.9 million in Q1 2024.
- A 5-year average of $12.9 million and a median of $12.8 million in 2023 frame the typical range for Raw Materials.
- The sharpest annual moves came in 2022 and 2023: Raw Materials surged 40.97% in 2022, then retreated 27.61% in 2023.
- Over 5 years, Raw Materials stood at $15.1 million in 2022, then fell by 24.85% to $11.3 million in 2023, then rose by 13.03% to $12.8 million in 2024, then increased by 0.98% to $13.0 million in 2025, then grew by 8.09% to $14.0 million in 2026.
- According to Business Quant data, Raw Materials over the past three periods registered $14.0 million, $13.8 million, and $13.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.00 Mn |
| Mar 31, 2026 | 13.75 Mn |
| Dec 31, 2025 | 12.95 Mn |
| Sep 30, 2025 | 12.70 Mn |
| Jun 30, 2025 | 11.24 Mn |
| Mar 31, 2025 | 11.83 Mn |
| Dec 31, 2024 | 12.83 Mn |
| Sep 30, 2024 | 11.85 Mn |
| Jun 30, 2024 | 11.49 Mn |
| Mar 31, 2024 | 10.86 Mn |
| Dec 31, 2023 | 11.35 Mn |
| Sep 30, 2023 | 11.44 Mn |
| Jun 30, 2023 | 12.85 Mn |
| Mar 31, 2023 | 14.26 Mn |
| Dec 31, 2022 | 15.10 Mn |
| Sep 30, 2022 | 15.80 Mn |
| Jun 30, 2022 | 15.18 Mn |
| Mar 31, 2022 | 13.26 Mn |
| Dec 31, 2021 | 12.68 Mn |
| Sep 30, 2021 | 12.01 Mn |